Stockreport

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

Aerie Pharmaceuticals, Inc.  (AERI) 
Last aerie pharmaceuticals, inc. earnings: 2/20 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aeriepharma.com/investor-relations
PDF Roclatan™ Successfully Achieves Primary Efficacy Endpoint in Mercury 2 Study Conference Call and Webcast Today, May 24, at 5:00 p.m. ET [Read more]